Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2022 Revenue
$27.5B
Source: Annual report / company filing
Gilead Sciences, Inc. reported $27.5B in revenue for fiscal year 2022. In 2023, revenue declined to $27.1B.
As the earliest year on record, 2022 marked the crest of the COVID antiviral Veklury near $5.5 billion, a pandemic-driven windfall that helped lift total product sales toward $27.5 billion.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $29.4B | — | +3.3% |
| FY2024 | $28.5B | $6.6B | +5.2% |
| FY2023 | $27.1B | — | -1.5% |
| FY2022 | $27.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.